HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Walter Berger Selected Research

Epidermal Growth Factor (EGF)

1/2018FGF2 and EGF induce epithelial-mesenchymal transition in malignant pleural mesothelioma cells via a MAPKinase/MMP1 signal.
11/2015EGFR is not a major driver for osteosarcoma cell growth in vitro but contributes to starvation and chemotherapy resistance.
9/2015Sensitivity of Melanoma Cells to EGFR and FGFR Activation but Not Inhibition is Influenced by Oncogenic BRAF and NRAS Mutations.
7/2012Trivanillic polyphenols with anticancer cytostatic effects through the targeting of multiple kinases and intracellular Ca2+ release.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Walter Berger Research Topics

Disease

163Neoplasms (Cancer)
05/2024 - 03/2002
25Melanoma (Melanoma, Malignant)
09/2019 - 04/2002
17Glioblastoma (Glioblastoma Multiforme)
01/2023 - 03/2002
14Glioma (Gliomas)
08/2023 - 03/2002
14Carcinoma (Carcinomatosis)
01/2022 - 02/2006
14Hepatocellular Carcinoma (Hepatoma)
10/2021 - 11/2002
13Colonic Neoplasms (Colon Cancer)
11/2023 - 01/2008
12Malignant Mesothelioma
01/2020 - 05/2011
10Mesothelioma
11/2023 - 05/2011
10Lung Neoplasms (Lung Cancer)
02/2021 - 02/2006
9Hypoxia (Hypoxemia)
01/2023 - 03/2011
9Brain Neoplasms (Brain Tumor)
01/2023 - 03/2002
9Colorectal Neoplasms (Colorectal Cancer)
04/2022 - 04/2015
9Neoplasm Metastasis (Metastasis)
02/2021 - 04/2006
7Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
09/2017 - 06/2005
6Breast Neoplasms (Breast Cancer)
04/2016 - 10/2003
5Urinary Bladder Neoplasms (Bladder Cancer)
05/2024 - 01/2022
5Leukemia
05/2024 - 04/2006
5Ovarian Neoplasms (Ovarian Cancer)
08/2019 - 07/2009
5Adenocarcinoma of Lung
08/2016 - 01/2013
4Sarcoma (Soft Tissue Sarcoma)
11/2022 - 10/2012
4Disease Progression
01/2020 - 09/2009
4Osteosarcoma (Osteogenic Sarcoma)
11/2018 - 11/2015
3Leukemia L1210
03/2023 - 01/2014
3Fibrosis (Cirrhosis)
01/2023 - 11/2006
3Pancreatic Neoplasms (Pancreatic Cancer)
01/2022 - 04/2016
3Hypersensitivity (Allergy)
01/2022 - 05/2011
3Ependymoma
01/2021 - 09/2017
3Meningioma (Meningiomas)
11/2018 - 03/2002
3Infections
04/2016 - 01/2013
3Liver Neoplasms (Liver Cancer)
03/2011 - 11/2006

Drug/Important Bio-Agent (IBA)

21Cisplatin (Platino)FDA LinkGeneric
05/2024 - 02/2006
20Proteins (Proteins, Gene)FDA Link
01/2023 - 03/2002
16ProdrugsIBA
01/2024 - 11/2014
15PlatinumIBA
01/2024 - 02/2008
14Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA
01/2022 - 10/2008
13Messenger RNA (mRNA)IBA
11/2023 - 11/2002
13Oxaliplatin (Eloxatin)FDA LinkGeneric
07/2023 - 02/2008
13LigandsIBA
01/2022 - 01/2009
10Biomarkers (Surrogate Marker)IBA
11/2023 - 10/2009
10Small Interfering RNA (siRNA)IBA
10/2023 - 02/2006
10Phosphotransferases (Kinase)IBA
12/2022 - 09/2009
10ErbB Receptors (EGF Receptor)IBA
09/2017 - 10/2008
9Telomerase (Telomerase Reverse Transcriptase)IBA
01/2023 - 10/2003
9Tyrosine Kinase InhibitorsIBA
11/2022 - 10/2011
83-aminopyridine-2-carboxaldehyde thiosemicarbazone (triapine)IBA
09/2022 - 06/2012
8RutheniumIBA
01/2022 - 06/2010
8Erlotinib Hydrochloride (CP 358,774)FDA Link
09/2019 - 07/2009
7Doxorubicin (Adriamycin)FDA LinkGeneric
03/2023 - 10/2012
7MetalsIBA
01/2019 - 02/2008
7Antineoplastic Agents (Antineoplastics)IBA
01/2017 - 02/2008
6Fibroblast Growth Factors (Fibroblast Growth Factor)IBA
01/2022 - 01/2008
6Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
03/2021 - 05/2007
6DNA (Deoxyribonucleic Acid)IBA
08/2019 - 11/2006
6Temozolomide (Temodar)FDA LinkGeneric
05/2017 - 07/2009
5Type 4 Fibroblast Growth Factor ReceptorIBA
01/2022 - 01/2014
5ThiosemicarbazonesIBA
11/2020 - 06/2012
5multidrug resistance-associated protein 1IBA
04/2016 - 03/2002
4AlbuminsIBA
01/2024 - 03/2017
4AcidsIBA
08/2023 - 04/2016
4ponatinibIBA
11/2022 - 11/2018
4IntegrinsIBA
01/2022 - 05/2009
4KP 1339IBA
08/2021 - 06/2010
4Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
01/2020 - 06/2013
4nintedanibIBA
11/2018 - 08/2016
4Sorafenib (BAY 43-9006)FDA Link
05/2018 - 05/2009
4OsmiumIBA
02/2018 - 12/2012
4Epidermal Growth Factor (EGF)IBA
01/2018 - 07/2012
4GalliumIBA
12/2017 - 10/2009
4Member 1 Subfamily B ATP Binding Cassette TransporterIBA
04/2016 - 03/2002
4activin AIBA
03/2016 - 11/2006
4indazolium trans- (tetrachlorobis(1H- indazole)ruthenate (III))IBA
01/2014 - 10/2008
4Cytostatic AgentsIBA
09/2013 - 03/2007
3maleimideIBA
01/2024 - 03/2017
3SodiumIBA
02/2023 - 01/2017
3TrabectedinIBA
11/2022 - 10/2012
3Glutathione (Reduced Glutathione)IBA
11/2021 - 02/2013
3YK 4-279IBA
10/2020 - 11/2018
3sphaeropsidin AIBA
10/2020 - 10/2015
3Type 3 Fibroblast Growth Factor Receptor (Fibroblast Growth Factor Receptor 3)IBA
01/2020 - 12/2015
3VemurafenibIBA
09/2019 - 03/2015
3PD 173074IBA
12/2018 - 06/2017
3Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)IBA
01/2018 - 10/2011
3Methotrexate (Mexate)FDA LinkGeneric
12/2017 - 02/2006
3Protein Isoforms (Isoforms)IBA
01/2017 - 10/2011
3FollistatinIBA
03/2016 - 11/2006
3Activins (Activin)IBA
01/2016 - 03/2008
3Vascular Endothelial Growth Factor CIBA
01/2016 - 08/2012
3Mitogen-Activated Protein KinasesIBA
10/2014 - 05/2007
3major vault proteinIBA
11/2013 - 06/2005
3CardenolidesIBA
04/2013 - 09/2009
3Cardiac GlycosidesIBA
04/2013 - 09/2009
3narciclasineIBA
11/2010 - 02/2009

Therapy/Procedure

56Therapeutics
05/2024 - 12/2007
18Drug Therapy (Chemotherapy)
05/2024 - 10/2003
8Immunotherapy
04/2024 - 12/2016
5Precision Medicine
04/2024 - 10/2018
4Radiotherapy
09/2019 - 05/2011
4Transplantation
11/2018 - 04/2006
3Neoadjuvant Therapy
01/2019 - 10/2003